Equities research analysts at StockNews.com assumed coverage on shares of Cumberland Pharmaceuticals (NASDAQ:CPIX – Get Free Report) in a research note issued to investors on Saturday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.
Cumberland Pharmaceuticals Stock Performance
Shares of Cumberland Pharmaceuticals stock opened at $1.49 on Friday. Cumberland Pharmaceuticals has a 12 month low of $1.38 and a 12 month high of $2.36. The company has a quick ratio of 1.21, a current ratio of 1.37 and a debt-to-equity ratio of 0.59. The stock has a market cap of $21.14 million, a PE ratio of -2.53 and a beta of 0.23. The business has a fifty day simple moving average of $1.52 and a 200-day simple moving average of $1.76.
Cumberland Pharmaceuticals (NASDAQ:CPIX – Get Free Report) last announced its quarterly earnings data on Tuesday, May 7th. The specialty pharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter. Cumberland Pharmaceuticals had a positive return on equity of 0.21% and a negative net margin of 21.67%. The business had revenue of $8.50 million during the quarter.
About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
See Also
- Five stocks we like better than Cumberland Pharmaceuticals
- How to Use the MarketBeat Dividend Calculator
- Top 3 Defense Stocks That Should Be on Your Radar
- Comparing and Trading High PE Ratio Stocks
- Why This Banking Stock Might Be Nearing the Bottom of Its Cycle
- Insider Trades May Not Tell You What You Think
- MarketBeat Week in Review – 7/8 – 7/12
Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.